Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | PKM | P14618 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | AKR1C3 | P42330 | 15/20 | 0.55 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3280649 | 0.81 | AKR1C3 (0.76) | AKR1C3AKR1C1 | |
| SCHEMBL7828814 | 0.81 | TSHR (1.00) | TSHRMAPK1PKMSMN1; SMN2ALDH1A1 | |
| SCHEMBL3286988 | 0.77 | AKR1C3 (0.73) | SMN1; SMN2AKR1C3AKR1C1 | |
| SCHEMBL25734239 | 0.77 | ESR1 (0.58) | ALDH1A1AKR1C3AKR1C1 | |
| SCHEMBL4239496 | 0.76 | AKR1C3 (0.76) | ALDH1A1AKR1C3AKR1C1 | |
| SCHEMBL3282044 | 0.76 | AKR1C3 (0.73) | AKR1C3AKR1C1 | |
| SCHEMBL3284957 | 0.76 | AKR1C3 (0.73) | AKR1C3AKR1C1 | |
| SCHEMBL3281383 | 0.76 | AKR1C3 (0.69) | AKR1C3AKR1C1 | |
| SCHEMBL4012085 | 0.76 | AKR1C3 (0.73) | AKR1C3AKR1C1 | |
| SCHEMBL3287776 | 0.75 | AKR1C3 (0.66) | AKR1C3AKR1C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705017-B2 | Compounds for treatment of neurodegenerative diseases | EN VIVO PHARMACEUTICALS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-20060004041-A1 | Compounds for treatment of neurodegenerative diseases | ENVIVO PHARMACEUTICALS, INC. | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004041-A1 | Compounds for treatment of neurodegenerative diseases | HDAC5, HDAC6, HDAC3 | TSHR 4496/4885MAPK1 2946/4885PKM 1424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.